New York, USA, April 10, 2023 (GLOBE NEWSWIRE) -- Hypoxia Market Growing Significantly| Teclison Ltd., Merck, Eli Lilly and Company, Reven Pharmaceuticals, Biogen Expected to Boost Hypoxia Market
The dynamics of the hypoxia market is anticipated to change in the coming years owing to the improvement in the diagnosis methodologies, incremental healthcare spending across the world, and also due to the expected launch of many therapies during the forecast period.
DelveInsight’s Hypoxia Market Insights report includes a comprehensive understanding of current treatment practices, hypoxia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].
Key Takeaways from the Hypoxia Market Report
- As per DelveInsight analysis, the hypoxia market is expected to grow positively owing to several underline factors during the study period (2019–2032).
- As per Biogen 2022, it is estimated that nearly 2 million people in the United States and the European Union will have a stroke each year.
- Leading hypoxia companies such as Teclison, Merck, Eli Lilly, Reven Pharmaceuticals, Biogen, AesRx, Threshold Pharmaceuticals, GlaxoSmithKline, Roche, Global Blood Therapeutics, Akebia Therapeutics, and others are developing novel hypoxia drugs that can be available in the hypoxia market in the coming years.
- Some of the key therapies for hypoxia treatment include Tirapazamine, Belzutifan, Tirzepatide, Rejuveinix, TMS-007, Aes-103, TH-302, GSK2256294, RO7070179, GBT440, AKB-6548, and others.
- Several hypoxia therapies are awaiting approval, while some therapies are in the advanced stages of development.
Discover which therapies are expected to grab the major hypoxia market share @ Hypoxia Market Report
Hypoxia Overview
Hypoxia is a condition with insufficient oxygen at the tissue level to maintain appropriate homeostasis. This can be caused by either insufficient blood flow to the tissues or insufficient oxygen levels in the blood. Traditional causes of hypoxia include hypoventilation, ventilation-perfusion mismatch, the low oxygen concentration of the air, right-to-left shunting, or impaired diffusion. Long-term untreated hypoxia causes irreversible organ damage, including death.
The hypoxia symptoms can differ depending on the cause and severity of the condition. Coughing, wheezing, increased heart rate, headache, and bluish skin, lips, or toenails are common symptoms. (called cyanosis). Severe instances may result in fainting or seizures. A physical examination to assess the heart and lungs is usually used for hypoxia diagnosis. If hypoxia symptoms are identified, tests such as pulse oximetry and arterial blood gas analysis are done, and imaging tests such as MRI, CT scan, echocardiogram, or electroencephalogram (EEG) are performed in cases of cerebral hypoxia.
Hypoxia Epidemiology Segmentation
As per the study conducted by Myriam Lacerte et al. (2020), the incidence rates of Hypoxic Brain Injury are approximately 50 per 100,000 population and survival-to-discharge rates of roughly 8%, which represents over 10,000 patients per year in the United States alone.
The hypoxia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:
- Incident Cases of Stroke
- Incident cases associated with Hypoxic Stroke
- Diagnosed and Treatable Cases of Hypoxic Stroke
Download the report to understand which factors are driving hypoxia epidemiology trends @ Hypoxia Epidemiological Insights
Hypoxia Treatment Market
The treatment of vascular brain disorders has a significant clinical, financial, and social effect around the globe. Prevention of their occurrence through lifestyle changes and clinical antihypertensive medication is an important component of the therapy to lower the risk of stroke and the gradual decline in memory caused by the vascular malfunction. The most important treatment for cerebral hypoxia involves removing the source of oxygen deprivation and intensive physical, occupational, or speech therapy to teach the brain how to work around any damaged areas. Such therapy can be difficult and emotionally draining, but the more committed treatment methods are more effective. Hypoxia treatment is divided into three categories: maintaining patent airways, raising the oxygen concentration of inspired air, and improving diffusion capacity.
To know more about hypoxia treatment, visit @ Hypoxia Treatment Drugs
Key Hypoxia Therapies and Companies
- Tirapazamine: Teclison Ltd.
- Belzutifan: Merck Sharp & Dohme
- Tirzepatide: Eli Lilly and Company
- Rejuveinix: Reven Pharmaceuticals, Inc.
- TMS-007: Biogen
- Aes-103: AesRx, LLC
- TH-302: Threshold Pharmaceuticals
- GSK2256294: GlaxoSmithKline
- RO7070179: Roche
- GBT440: Global Blood Therapeutics
- AKB-6548: Akebia Therapeutics
Learn more about the FDA-approved drugs for hypoxia @ Drugs for Hypoxia Treatment
The dynamics of the hypoxia market are expected to change in the coming years due to the rising prevalence of the disease. In addition, the increasing awareness and rising healthcare spending across the globe will boost the growth of the hypoxia market. Moreover, the hypoxia pipeline is very robust; many potential therapies for hypoxia treatment are being investigated, and it is safe to predict that the treatment space will have a major effect on the hypoxia market during the forecast period. The anticipated introduction of new therapies with better efficacy and a further improvement in the diagnosis rate are all expected to drive the growth of the hypoxia market in the 7MM in the coming years.
However, the hypoxia market growth may be offset by failures and discontinuation of emerging therapies, unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the hypoxia market growth.
| Report Metrics | Details |
| Study Period | 2019–2032 |
| Coverage | 7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan] |
| Base Year | 2019 |
| Key Hypoxia Companies | Teclison Ltd., Merck Sharp & Dohme, Eli Lilly and Company, Reven Pharmaceuticals, Inc., Biogen, AesRx, LLC, Threshold Pharmaceuticals, GlaxoSmithKline, Roche, Global Blood Therapeutics, Akebia Therapeutics, and others |
| Key Hypoxia Therapies | Tirapazamine, Belzutifan, Tirzepatide, Rejuveinix, TMS-007, Aes-103, TH-302, GSK2256294, RO7070179, GBT440, AKB-6548, and others |
Scope of the Hypoxia Market Report
- Therapeutic Assessment: Hypoxia current marketed and emerging therapies
- Hypoxia Market Dynamics: Attribute Analysis of Emerging Hypoxia drugs
- Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
- Unmet Needs, KOL’s views, Analyst’s views, Hypoxia Market Access and Reimbursement
Discover more about hypoxia drugs in development @ Hypoxia Clinical Trials
Table of Contents
| 1. | Hypoxia Market Key Insights |
| 2. | Hypoxia Market Report Introduction |
| 3. | Hypoxia Market Overview at a Glance |
| 4. | Hypoxia Market Executive Summary |
| 5. | Disease Background and Overview |
| 6. | Hypoxia Treatment and Management |
| 7. | Hypoxia Epidemiology and Patient Population |
| 8. | Patient Journey |
| 9. | Hypoxia Marketed Drugs |
| 10. | Hypoxia Emerging Drugs |
| 11. | Seven Major Hypoxia Market Analysis |
| 12. | Hypoxia Market Outlook |
| 13. | Potential of Current and Emerging Therapies |
| 14. | KOL Views |
| 15. | Hypoxia Market Drivers |
| 16. | Hypoxia Market Barriers |
| 17. | Unmet Needs |
| 18. | SWOT Analysis |
| 19. | Appendix |
| 20. | DelveInsight Capabilities |
| 21. | Disclaimer |
| 22. | About DelveInsight |
Related Reports
Hypoxia Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted hypoxia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Hypoxia Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key hypoxia companies, including GlaxoSmithKline, Roche, Global Blood Therapeutics, Akebia Therapeutics, among others.
Ischemic Stroke Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key ischemic stroke companies, including Suzhou Yabao Pharmaceutical R&D Co., Ltd., Prolong Pharmaceuticals, Nanjing Yoko Biomedical Co., Ltd., among others.
Acute Ischemic Stroke Pipeline
Acute Ischemic Stroke Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key acute ischemic stroke companies including Genentech, Pharmazz, GNT Pharma, NoNO, among others.
Acute Ischemic Stroke Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key acute ischemic stroke companies, including Genentech, Pharmazz, GNT Pharma, NoNO, among others.
Acute Ischemic Stroke Epidemiology
Acute Ischemic Stroke Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical, and forecasted acute ischemic stroke epidemiology in the 7MM.
Other Trending Reports
Treatment Resistant Depression Market | Advanced Renal Cell Carcinoma Market | Hypoxia Market | Centronuclear Myopathy Market | Head And Neck Squamous Cell Carcinoma Market | Acquired Immunodeficiency Syndrome Market | Acute Intermittent Porphyria Market | Neurovascular Devices Market | Defibrillators Market | Ventricular Hypertrophy Market | Urolithiasis Market | Alopecia Areata Market | Autonomic Dysfunction Market | Acute Ischemic Stroke Ais Market | Adenoid Cystic Carcinoma Market | Aspergillosis Market | Biliary Atresia Market | Biliary Tumor Market | Chronic Inducible Urticaria Market | Chronic Insomnia Market | Critical Limb Ischemia Market | Endometriosis Pain Market | Generalized Anxiety Disorder Gad Market | Hallux Valgus Market | Hemophilia B Market | Immunologic Deficiency Syndrome Market | Neuroblastoma Market | Neuromodulation Devices Market | Neurovascular Thrombectomy Devices Market | Osteosarcoma Market | Pemphigus Vulgaris Market | Progressive Familial Intrahepatic Cholestasis Market | Pruritus Market | Radiation Toxicity Market | Pulmonary Hypertension Associated With Interstitial Lung Disease Market | Cluster Headaches Market | Foot And Ankle Devices Market | Intravenous Immunoglobulin Market | Bile Duct Neoplasm Market | Blood Glucose Monitoring Systems Market | Rett Syndrome Market | Tissue Heart Valves Market | Cardiac Biomarkers Testing Devices Market | Subscription Healthcare | Hepatorenal Syndrome Market | Central Venous Catheters Market | Continuous Renal Replacement Therapy Machines Market | Nonalcoholic Steatohepatitis Market | Necrotizing Enterocolitis Market | Cardiac Amyloidosis Market | Artificial Iris Market | Aortic Aneurysm Stent Grafts Market | Polypoidal Choroidal Vasculopathy Market | Adrenal Crisis Market | Hearing Implants Market | Image Guided Surgery Devices Market | Angioedema Market | Bladder Cancer Market
Related Healthcare Blogs
Upcoming Cardiovascular Diseases Drugs
Key Companies in the Cardiology Segment
Related Healthcare Services
Healthcare Competitive Intelligence Services
Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect with us on LinkedIn|Facebook|Twitter
